--- title: "Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring" type: "News" locale: "en" url: "https://longbridge.com/en/news/293376901.md" description: "Tempus AI agreed to acquire Personalis for $1.5 billion to expand its presence in the $20 billion minimal residual disease (MRD) cancer monitoring market. The deal aims to enhance Tempus's MRD capabilities, with William Blair viewing it as a strategic fit despite high valuation multiples and profitability concerns. BNP Paribas noted the combination could increase competitive pressure on rival Natera. Tempus shares recovered from initial selloffs to trade up nearly 2%." datetime: "2026-07-21T18:52:05.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293376901.md) - [en](https://longbridge.com/en/news/293376901.md) - [zh-HK](https://longbridge.com/zh-HK/news/293376901.md) --- # Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring On Monday, **Tempus AI, Inc.** (NASDAQ:TEM) agreed to acquire **Personalis, Inc.** (NASDAQ:PSNL), aiming to advance cancer monitoring through enhanced minimal residual disease (MRD) capabilities. Tempus AI shares erased early losses and recovered after an initial selloff tied to the company’s acquisition of Personalis. ## Tempus AI Targets $20 Billion MRD Market The acquisition, valued at $1.5 billion, is set to expand Tempus’ reach in the MRD market. Tempus claims it presents a $20 billion opportunity. **William Blair** has a favorable view of the strategic fit and expects Personalis’ growth and profitability trajectory to be meaningfully different inside of Tempus than it would have been as a standalone company. Both the clinical data and early commercial trajectory for NeXT Personal suggest Tempus is well-positioned to be a much larger player in the underpenetrated $20 billion TAM MRD market. **Read Also: Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts** ## William Blair Sees Long-Term Growth But Flags Profitability Questions The acquisition multiple is high at ~14 times 2027 consensus sales, though analyst **Matt Larew** wrote that the consensus likely understates Personalis’ 2027 revenue outlook given recent MolDX approvals and Tempus’ ability to further leverage its commercial infrastructure. The other pressure point will be profitability given Personalis’ clear loss-making position (consensus adjusted EBITDA of -$90 million for 2027) and Tempus’s commitment to be EBITDA and FCF positive in 2027. Management argued that the timing of the acquisition is coincident with Personalis reaching an inflection point, with several years of commercial and reimbursement investment likely to yield enhanced ASPs and margins moving forward. William Blair rates Tempus AI shares Market Perform. For multiple expansion to materialize, analyst Larew expects investors will want to see additional positive proof points on recent M&A contributing to numbers and more clarity on the growth profile and durability of the data business. **Read Also: Cathie Wood’s Tempus AI Bet Is Bleeding — And the Chart Looks Worse Than Wall Street Thinks** ## BNP Paribas Says Deal Could Increase Pressure On Natera **BNP Paribas** wrote that while Tempus and Personalis already had a partnership in place, the combination may result in a stronger competitor for **Natera Inc.** (NASDAQ:NTRA) in the MRD market. Analyst **Navann Ty** wrote that Natera maintains a defensible, leadership position in the space, with a solid pipeline of ongoing clinical trials. BNP Paribas maintains Neutral on Natera as the company continues to progress towards catalysts but views the current valuation as fair. **TEM Stock Price Activity**: Tempus AI shares were up 1.96% at $49.36 at the time of publication on Tuesday, according to Benzinga Pro data. _Photo via Shutterstock_ **Read Also: Chinese Enterprise Software Firm Yonyou Seeks Hong Kong IPO** ### Related Stocks - [TEM.US](https://longbridge.com/en/quote/TEM.US.md) - [PSNL.US](https://longbridge.com/en/quote/PSNL.US.md) - [NTRA.US](https://longbridge.com/en/quote/NTRA.US.md) - [TEMT.US](https://longbridge.com/en/quote/TEMT.US.md) - [BMY.US](https://longbridge.com/en/quote/BMY.US.md) - [BNPQY.US](https://longbridge.com/en/quote/BNPQY.US.md) - [600588.CN](https://longbridge.com/en/quote/600588.CN.md) - [CELG.RT.US](https://longbridge.com/en/quote/CELG.RT.US.md) ## Related News & Research - [Dear Tempus AI Stock Fans, Mark Your Calendars for July 30](https://longbridge.com/en/news/294373596.md) - [Tempus AI (TEM) Expected to Announce Earnings on Thursday](https://longbridge.com/en/news/293593325.md) - [Tempus AI (TEM) Drops on $1.7B Personalis Deal; Needham Analyst Calls the Slide a "Market Misread"](https://longbridge.com/en/news/293251564.md) - [TEM: A $1.5B acquisition merges AI oncology and MRD tech to lead in cancer monitoring](https://longbridge.com/en/news/293215484.md) - [Tempus AI agrees to buy Personalis for USD 16.25 per share in USD 1.5 billion deal](https://longbridge.com/en/news/293214621.md)